Original Article

You have full text access to this OnlineOpen article

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer†

  1. Xianglin L. Du MD, PhD1,‡,*,
  2. Rui Xia MS1,
  3. Chih-Chin Liu MS1,
  4. Janice N. Cormier MD, MPH2,
  5. Yan Xing PhD2,
  6. Dale Hardy PhD1,
  7. Wenyaw Chan PhD3,
  8. Keith Burau PhD3

Article first published online: 11 AUG 2009

DOI: 10.1002/cncr.24621

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5296–5308, 15 November 2009

Additional Information

How to Cite

Du, X. L., Xia, R., Liu, C.-C., Cormier, J. N., Xing, Y., Hardy, D., Chan, W. and Burau, K. (2009), Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer, 115: 5296–5308. doi: 10.1002/cncr.24621

Author Information

  1. 1

    Division of Epidemiology, University of Texas School of Public Health, Houston, Texas

  2. 2

    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Division of Biostatistics, University of Texas School of Public Health, Houston, Texas

  1. ‡

    Fax: (713)500-9264

*University of Texas School of Public Health, 1200 Herman Pressler, RAS-E631, Houston, TX 77030

  1. †

    We acknowledge the efforts of the NCI, CMS, IMS, and the SEER registries in the creation of this database.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 11 AUG 2009
  3. Manuscript Accepted: 7 MAY 2009
  4. Manuscript Revised: 1 MAY 2009
  5. Manuscript Received: 17 NOV 2008

Funded by

  • Agency for Healthcare Research and Quality. Grant Number: R01-HS016743

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (249K)

References

  • 1
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 2
    U.S. Food and Drug Administration. Managing the Risks From Medical Product Use. Pt III: How does FDA conduct postmarketing surveillance and risk assessment? Available at: http://www.fda.gov/oc/tfrm/Part3.html Accessed May 11, 2006.
  • 3
    Perry MC, Yarbro JW. Toxicity of chemotherapy. Orlando, Florida: Grune & Stratton; 1984.
  • 4
    Baquiran DC. Lippincott's Cancer Chemotherapy Handbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
  • 5
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; 105-109.
  • 6
    Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999; 17: 3374-3388.
  • 7
    Shapiro CL, et al. Side Effects of Adjuvant Treatment of Breast Cancer. N Engl J Med. 2001; 344: 1997-2008.
  • 8
    Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000; 18: 1412-1422.
  • 9
    Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; 135-142.
  • 10
    Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol. 2002; 20: 4591-4596.
  • 11
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109: 3122-3131.
  • 12
    Loerzel VW, Dow KH. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs. 2003; 7: 557-562.
  • 13
    Fumoleau P, Roché H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French adjuvant study group results. Ann Oncol. 2006; 17: 85-92.
  • 14
    Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25: 3991-4008.
  • 15
    Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007; 50: 1435-1441.
  • 16
    Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 1383-1389.
  • 17
    Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003; 18: 57-60.
    Direct Link:
  • 18
    Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285: 437-443.
  • 19
    Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993; 269: 2765-2768.
  • 20
    Wu AW. Adverse drug events and near misses: who's counting? Am J Med. 2000; 109: 166-168.
  • 21
    Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999; 281: 824-829.
  • 22
    Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA. 1999; 281: 841-844.
  • 23
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287: 2215-2220.
  • 24
    Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet. 2000; 356: 1339-1343.
  • 25
    Agency for Healthcare Research and Quality. Research Activities. August 2004, No. 288. Postmarketing drug surveillance could be improved. Available at: http://www.ahrq.gov/research/aug04/0804RA11.htm#head3 Accessed May 11, 2006.
  • 26
    US Food and Drug Administration. Report to Congress: reports on postmarketing studies. Available at: http://www.fda.gov/cber/fdama/pstmrktfdama130.htm Accessed May 11, 2006.
  • 27
    Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004; 292: 2647-2650.
  • 28
    Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clinical Pharmacology & Therapeutics. 2004; 75: 491-494.
  • 29
    Butler RN, Nyberg JP. Improving Drug Safety: The Importance of Postmarketing Drug Surveillance. Report Issue IB13-2004 of the International Longevity Center–USA. Available at: http://www.ilcusa.org/_lib/pdf/postmarketing.pdf Accessed May 12, 2006.
  • 30
    US Food and Drug Administration. FDA acts to strengthen the safety program for marketed drugs [press release]. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01131.html Accessed May 12, 2006.
  • 31
    Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005; 23: 8597-8605.
  • 32
    Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25: 3808-3815.
  • 33
    National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/index.html Accessed October 20, 2008.
  • 34
    U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information; 1996.
  • 35
    Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol. 2001; 19: 1455-1461.
  • 36
    Du XL, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999; 52: 463-470.
  • 37
    Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005; 104: 913-924.
    Direct Link:
  • 38
    Penman AD, Johnson WD. A SAS program for calculating cumulative incidence of events (with confidence limits) and number at risk at specified time intervals with partially censored data. Comput Methods Programs Biomed. 2008; 89: 50-55.
  • 39
    Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess. 2007; 11: iii, ix-x, 1-84.
  • 40
    Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. J Clin Oncol. 2008; 26: 1223-1230.
  • 41
    Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008; 26: 1201-1203.
  • 42
    Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
  • 43
    Steingart R. Mechanisms of late cardiovascular toxicity from cancer chemotherapy. J Clin Oncol. 2005; 23: 9051-9052.
  • 44
    Portera CC, Swain SM. The heart of the matter. J Clin Oncol. 2007; 25: 3794-3796.
  • 45
    Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008; 14: 14-24.
View Full Article (HTML) Get PDF (249K)